Breaking News
FONT-SIZE Plus   Neg
Share SHARE
mail  E-MAIL

Response Genetics To Sell 8 Mln Common Shares To GlaxoSmithKline For $1.10/Shr

RELATED NEWS
Trade RGDX now with 
9/13/2012 9:22 AM ET

Response Genetics, Inc. (RGDX: Quote), a California-based life-science company, Thursday said it entered into a private purchase agreement with GlaxoSmithKline (GSK) and one of its stockholders to raise $8.8 million through the private placement of 8 million issued common shares of Response, for a price of $1.10 per share.

Thomas Bologna, chairman and CEO of Response Genetics stated, "The capital raised will help support our continued efforts in building a sustainable business of high value genetic tests for cancer patients as well as a premier pharmaceutical services business."

The signing of the purchase agreement and closing of the financing occurred on September 13, 2012.

Response Genetics shares are currently up 21.11%, trading at $1.09 on the Nasdaq.

Click here to receive FREE breaking news email alerts for Response Genetics Inc and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
NASA's Cassini spacecraft, now exploring Saturn, will take a picture of Earth from a distance of hundreds of millions of miles on July 19. NASA is inviting the public to help acknowledge the historic interplanetary portrait as it is being taken. Earth will appear as a small, pale blue dot between the rings of Saturn in the image, which will be part of a mosaic, or multi-image portrait, of the A leading indicator of Australian economic activity continued to signal above-trend growth for the economy in the coming quarters, a report from Westpac and Melbourne Institute showed Wednesday. The annualized growth rate of the leading index, which indicates the likely pace of economic activity three to nine months into the future, was 5.4 percent in April, comfortably above its long term trend. Publishing and design software maker Adobe Systems Inc. said Tuesday after the markets closed that its second quarter profit fell 66% from last year, hurt by lower revenue as well as higher costs and expenses. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations and its quarterly revenue was in line with analysts' forecast.
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.